الفهرس 
Hepatitis C virus (HCV)Only 14 pages are availabe for public view
 |  | from | 123 |  |  |
| | | from | 123 | | |
Abstract
Summary The availability of DAAs with excellent efficacy and good tolerability profiles offer a unique opportunity to achieve HCV elimination worldwide. DAA combinations can now cure HCV in more than 95% of patients with HCV infection after 12 weeks of treatment. The purpose of this work was to evaluate detection of HCVcAg in the serum as an early predictor of SVR to DAAs in Egyptian patients with chronic HCV infection. This prospective cohort study was carried out in the Viral Hepatitis Treatment Unit at Tanta University Teaching Hospital. The study included 85 patients with chronic HCV infection, who were treated according to NCCVH treatment protocol with SOF+DCV+RBV for 12 weeks. Patients received antiviral therapy and completed their course of HCV therapy. As regard baseline demographic and laboratory data, all parameters showed non-significant differences. HCVcAg detection were done after 10 days of starting treatment for every patient. It was negative in 79 patients; 78 of them achieved SVR and only one patient did not achieve SVR, while it was positive in 6 patients; all of whom did not achieve SVR. HCVcAg had sensitivity 100%, specificity 98.73%, positive predictive value was 85.71%, negative predictive value 100% and accuracy 98.82%. HCVcAg had significant correlation with HCV RNA detection and HCVcAg may consequently be used to monitor the response to antiviral therapy in chronically infected patients, given the generally favorabl